Abilify (Schizophrenia) - Forecast and Market Analysis to 2022
|出版日期||內容資訊||英文 44 Pages
|Abilify(精神分裂症):市場預測與分析 Abilify (Schizophrenia) - Forecast and Market Analysis to 2022|
|出版日期: 2014年02月28日||內容資訊: 英文 44 Pages||
Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms, auditory or visual hallucinations, are often accompanied by fixed, false, and often paranoid beliefs, called delusions. These two features are often combined with learning and cognitive deficits. WHO experts have estimated that roughly 24 million people are affected by schizophrenia worldwide. While the arrival of atypical antipsychotics has greatly expanded pharmacologic treatment options over the past two decades, the current drug market does not treat the negative and cognitive symptoms that are associated with the disease. GlobalData expects that the growing popularity of long-acting injectable (LAI) antipsychotics, along with the arrival of novel treatments that achieve higher efficacy in negative- and cognitive-predominant patients, will serve to stimulate growth in the marketplace over the forecast period. Country-specific treatment recommendations and policy implementation will be an essential metric for determining future mental health services in the 7MM.
Otsuka's Abilify (aripiprazole) is a quinolone piperidine derivative with partial agonist properties at the D2 dopaminergic receptor. By acting as a partial agonist at this dopamine receptor subtype, Abilify presents a unique mechanism within the schizophrenia drug portfolio: partial D2 agonism modulates dopaminergic activity in areas where dopamine may be high or low, such as in the mesolimbic and mesocortical areas of the schizophrenic brain.